Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin, Acetazolamide, and Metolazone as Add-on Therapies to Loop Diuretics in Acute Decompensated Heart Failure
NCT07372040Phase 2Recruiting
- Sponsor
- Tanta University
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin, acetazolamide, metolazone in heart failure (HF), sponsored by Tanta University. Started Feb 2026; status: recruiting.
02
Drugs
empagliflozinacetazolamidemetolazone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07372040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372040.